DATE & PLACE
28 & 29 October 2022 (arrival on 27 October)
VENUE
Sheraton Oman Hotel
40 Way, Muscat 112, Oman
REGISTRATION INFORMATION
Registration is obligatory for access to the expert meeting. Please register here.
LEARNING OBJECTIVES
After attending the meeting, participants should be able to:
- Discuss measures to improve the diagnostic process for SMA at your clinic
- Examine the evolving treatment landscape in SMA
- Discuss practical considerations for the implementation of gene therapy
- Develop individualized care plans for your patients with SMA, and explain how multidisciplinary management could be optimized
- Outline measures for optimal integration of novel treatments and identify relevant criteria for patient selection
TARGET AUDIENCE
This meeting is intended for neurologists and neuromuscular disease specialists from the Middle East region who are responsible for the diagnosis and management of patients with SMA.
LANGUAGE
The official language of this educational meeting is English.
CONTACT
Should you have any questions about this educational meeting, please email [email protected].
SMA Expert Exchange: Novel treatments in clinical practice is organized by Ology Medical Education, a global provider of independent medical education that develops CME initiatives for the international medical and scientific community.
Final programme to be announced prior to the meeting.
Thursday 27 October, 2022
Arrivals
| 18:30–21:30 | Welcome dinner |
Friday 28 October, 2022
| 09:00–09:20 | Welcome lecture on current clinical practice in SMA Haitham Osman Elbashir |
Session 1: Improving the diagnostic process
| 09:20–09:50 | Expert presentation and Q&A on the diagnosis of SMA Mohammed Al-Muhaizea |
| 09:50–10:30 | Small group activities/workshop sessions on diagnostic challenges and screening programmes Moderated by the steering committee |
| 10:30–10:50 | Group presentations and moderated discussion |
| 10:50–11:50 | Refreshment break |
Session 2: Implementing novel treatments
| 11:50–12:50 | Expert presentation and Q&A on the evolving treatment landscape for SMA Laurent Servais |
| 12:50–13:50 | Lunch break |
| 13:50–14:50 | Patient case presentations: gene therapy in clinical practice Mohammed Al-Muhaizea, Haitham Osman Elbashir, Tawfeg Ben-Omran |
| 14:50–15:50 | Refreshment break |
| 15:50–16:10 | Small group activities/workshop sessions on the implementation of novel treatments Moderated by the steering committee |
| 16:10–17:10 | Group presentations and moderated discussion |
| 17:10–18:10 | Panel discussion about the implementation of novel treatments Moderated by Mohammed Al-Muhaizea Conclusions of the day Tawfeg Ben-Omran |
| 19:30-21:30 | Dinner |
Saturday 29 October, 2022
| 09:00-09:10 | Overview of the programme for Day 2 Haitham Osman Elbashir |
Session 3: Optimizing multidisciplinary care
| 09:10–09:50 | Case-based expert presentation and Q&A on pulmonary care in SMA Rania Abusamra Abdelkarim |
| 09:50–10:30 | Case-based expert presentation and Q&A on physiotherapy in SMA Elena Mazzone |
| 10:30–11:30 | Small group activities/workshop sessions on multidisciplinary care in SMA Moderated by the steering committee |
| 11:30–12:10 | Refreshment break |
| 12:10–13:10 | Group presentations and moderated discussion |
| 13:10–13:20 | Outlook on the future of SMA care Tawfeg Ben-Omran |
| 13:20–14:00 | Optional lunch |
Departures
STEERING COMMITTEE
Mohammed Al-Muhaizea, MD
King Faisal Hospital and Research Centre
Riyadh, Saudi Arabia
Tawfeg Ben-Omran, MD, FRCPC, FCCMG, FACMG
Sidra Medicine
Doha, Qatar
Weill Cornell Medical College,
Dohar, Qatar, and New York, NY, USA
Haitham Osman Elbashir, MD
Al Jalila Children Specialty Hospital
Dubai, United Arab Emirate
FACULTY
Rania Abusamra Abdelkarim,MBChB, FRCPCH, HERMES, CCT(UK)
Elena Mazzone, PT
Laurent Servais, MD, PhD
Disclosures of conflicts of interest
Mohammed Al-Muhaizea, MD
Receipt of grants/research supports: Novartis Gene Therapies, PTC Therapeutics, Roche
Receipt of honoraria or consultation fees: Biogen Inc., Novartis Gene Therapies, PTC Therapeutics, Roche
Participation in a company sponsored speaker’s bureau: Biogen Inc., Novartis Gene Therapies, Roche
Tawfeg Ben-Omran, MD, FRCPC, FCCMG, FACMG
Nothing to disclose.
Haitham Osman Elbashir, MD
Receipt of honoraria or consultation fees: Biogen Inc., Novartis Gene Therapies, Pfizer Inc., PTC Therapeutics, Roche
Participation in a company sponsored speaker’s bureau: Biogen Inc., Novartis Gene Therapies, Pfizer Inc., PTC Therapeutics, Roche
FACULTY
Rania Abusamra Abdelkarim, MD, MBChB, FRCPCH, HERMES, CCT
Nothing to disclose.
Elena Mazzone, PT
Receipt of honoraria or consultation fees: Biogen Inc., Novartis Gene Therapies, Roche, Scholar Rock
Laurent Servais, MD, PhD
Receipt of grants/research supports: Biogen Inc., Novartis Gene Therapies, Roche
Receipt of honoraria or consultation fees: BioHaven, Biogen Inc., Novartis Gene Therapies, Roche, Scholar Rock
Participation in a company sponsored speaker’s bureau: Biogen Inc., Novartis Gene Therapies, Roche
PLANNERS AND MANAGERS
Ology Medical Education planners and managers have nothing to disclose.
An application for accreditation has been submitted to UEMS-EACCME® for 10.0 ECMEC® credits.
DISCLAIMER
This event was organized to promote the exchange and dissemination of scientific and medical information only, with no promotional activity permitted. The views expressed during each presentation are those of the speaker only, and do not necessarily reflect the views of the organizers or sponsors. The presentations may discuss therapeutic products that have not been approved, or off-label use of certain products. All content is provided for general educational purposes only and should not in any way be considered as advisory. It is the responsibility of the healthcare professional to verify all information and data before treating patients or using any therapies described. All presentations are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) any part of the material presented, you must obtain all the necessary permissions from the publisher, original author, and any other current copyright owner.
This programme has been made possible thanks to an unrestricted independent educational grant received from Novartis Gene Therapies (formerly AveXis).
Please register here for the SMA Expert Exchange: Novel treatments in clinical practice meeting.
There is no registration fee for this meeting. Travel (economy round-trip flights and transfer to meeting venue from the airport) and accommodation for two nights will be organized for all participants by Ology Medical Education.
Any alternative travel arrangements and incidental costs made by the participants will not be reimbursed. Following your registration, you will be contacted by the organizers for further details so that we can arrange your travel.
EDUCATIONAL PARTNER
Ology Medical Education
[email protected]
SMA Expert Exchange: Novel treatments in clinical practice
28 & 29 October 2022 in Muscat, Oman
Register
Welcome to SMA Expert Exchange: Novel treatments in clinical practice, an international expert meeting on spinal muscular atrophy (SMA) management.
During this event you will take part in a 1.5-day programme, comprising engaging activities including discussions of patient cases and workshop sessions addressing local challenges.
The meeting will also feature expert lectures and panel discussions, with opportunities for you to share experiences with your peers and receive feedback on clinical issues from leading global experts.
SMA Expert Exchange will help ensure that you are up to date with the latest data and thinking, offering practical guidance on early diagnosis, the implementation of novel treatment options, and how to optimize multidisciplinary care to meet local needs.
Related activities
